HT-0712 – (617720-02-2)

HT-0712 is an experimental cognitive-enhancing molecule (nootropic) currently undergoing clinical trials. It is a Phosphodiesterase Type 4 (PDE4) inhibitor, which increases cAMP levels in neurons, potentially activating cAMP response element-binding proteins (CREB) involved in long-term memory formation.

It was originally discovered as part of an anti-inflammatory program by Inflazyme Pharmaceuticals. Research indicates that HT-0712 enhances memory formation in mice and may be effective in treating age-associated memory impairment in humans. Its side effects are not yet fully understood. The drug has shown promise in improving hippocampus-dependent memory and CREB-regulated gene expression in aged mice, suggesting potential therapeutic applications for cognitive decline.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/HT-0712
https://www.medchemexpress.com/ht-0712.html
https://www.medkoo.com/products/12297
https://pubmed.ncbi.nlm.nih.gov/24964813/